Difference between revisions of "Drug index"

From HemOnc.org - A Hematology Oncology Wiki
Jump to navigation Jump to search
Line 21: Line 21:
 
*[[AG-221]] '''in clinical trials'''
 
*[[AG-221]] '''in clinical trials'''
 
*[[Aldesleukin (Proleukin)]]
 
*[[Aldesleukin (Proleukin)]]
−
*[[Alectinib (Alecensa)]] '''FDA approved 12/11/2015'''
+
*[[Alectinib (Alecensa)]]
 
*[[Alemtuzumab (Campath)]]
 
*[[Alemtuzumab (Campath)]]
 
*[[Alendronate (Fosamax)]]
 
*[[Alendronate (Fosamax)]]
Line 126: Line 126:
 
*[[Clofarabine (Clolar)]]
 
*[[Clofarabine (Clolar)]]
 
*[[Clopidogrel (Plavix)]]
 
*[[Clopidogrel (Plavix)]]
−
*[[Cobimetinib (Cotellic)]] '''FDA approved 11/10/2015'''
+
*[[Cobimetinib (Cotellic)]]
 
*[[Coltuximab ravtansine (CoR, SAR3419)]] '''in clinical trials'''
 
*[[Coltuximab ravtansine (CoR, SAR3419)]] '''in clinical trials'''
 
*[[Copanlisib (BAY 80-6946)]] '''in clinical trials'''
 
*[[Copanlisib (BAY 80-6946)]] '''in clinical trials'''
Line 154: Line 154:
 
*[[Dalteparin (Fragmin)]]
 
*[[Dalteparin (Fragmin)]]
 
*[[Dapsone (Aczone)]]
 
*[[Dapsone (Aczone)]]
−
*[[Daratumumab (Darzalex)]] '''FDA approved 11/16/2015'''
+
*[[Daratumumab (Darzalex)]]
 
*[[Darbepoetin alfa (Aranesp)]]
 
*[[Darbepoetin alfa (Aranesp)]]
 
*[[Dasatinib (Sprycel)]]
 
*[[Dasatinib (Sprycel)]]
Line 161: Line 161:
 
*[[Decitabine (Dacogen)]]
 
*[[Decitabine (Dacogen)]]
 
*[[Deferasirox (Exjade)]]
 
*[[Deferasirox (Exjade)]]
−
*[[Deferasirox (Jadenu)]] '''FDA approved 3/30/2015'''
+
*[[Deferasirox (Jadenu)]]
 
*[[Deferiprone (Ferriprox)]]
 
*[[Deferiprone (Ferriprox)]]
 
*[[Deferoxamine (Desferal)]]
 
*[[Deferoxamine (Desferal)]]
Line 173: Line 173:
 
*[[Diethylstilbestrol (DES)]]
 
*[[Diethylstilbestrol (DES)]]
 
*[[Dinaciclib (SCH 727965)]] '''in clinical trials'''
 
*[[Dinaciclib (SCH 727965)]] '''in clinical trials'''
−
*[[Dinutuximab (Unituxin)]] '''FDA approved 3/10/2015'''
+
*[[Dinutuximab (Unituxin)]]
 
*[[Diphenhydramine (Benadryl)]]
 
*[[Diphenhydramine (Benadryl)]]
 
*[[Discodermolide (XAA296)]] '''in clinical trials'''
 
*[[Discodermolide (XAA296)]] '''in clinical trials'''
Line 193: Line 193:
 
|}
 
|}
 
*[[Eculizumab (Soliris)]]
 
*[[Eculizumab (Soliris)]]
−
*[[Edoxaban (Savaysa)]] '''FDA approved 1/18/2015'''
+
*[[Edoxaban (Savaysa)]]
−
*[[Elotuzumab (Empliciti)]] '''FDA approved 11/30/2015'''
+
*[[Elotuzumab (Empliciti)]]
 
*[[Eltrombopag (Promacta)]]
 
*[[Eltrombopag (Promacta)]]
 
*[[Emepepimut-S (Stimuvax)]] '''in clinical trials'''
 
*[[Emepepimut-S (Stimuvax)]] '''in clinical trials'''
Line 232: Line 232:
 
*[[Filanesib (ARRY-520)]] '''in clinical trials'''
 
*[[Filanesib (ARRY-520)]] '''in clinical trials'''
 
*[[Filgrastim (Neupogen)]]
 
*[[Filgrastim (Neupogen)]]
−
*[[Filgrastim-sndz (Zarxio)]] '''FDA approved 3/6/2015'''
+
*[[Filgrastim-sndz (Zarxio)]]
 
*[[Finasteride (Proscar)]]
 
*[[Finasteride (Proscar)]]
 
*[[Fluorouracil (5-FU)]]
 
*[[Fluorouracil (5-FU)]]
Line 291: Line 291:
 
*[[Ibrutinib (Imbruvica)]]
 
*[[Ibrutinib (Imbruvica)]]
 
*[[Idarubicin (Idamycin)]]
 
*[[Idarubicin (Idamycin)]]
−
*[[Idarucizumab (Praxbind)]] '''FDA approved 10/16/2015'''
+
*[[Idarucizumab (Praxbind)]]
 
*[[Idelalisib (Zydelig)]]
 
*[[Idelalisib (Zydelig)]]
 
*[[Ifosfamide (Ifex)]]
 
*[[Ifosfamide (Ifex)]]
Line 304: Line 304:
 
*[[Ipilimumab (Yervoy)]]
 
*[[Ipilimumab (Yervoy)]]
 
*[[Irinotecan (Camptosar)]]
 
*[[Irinotecan (Camptosar)]]
−
*[[Irinotecan liposome (Onivyde)]] '''FDA approved 10/22/2015'''
+
*[[Irinotecan liposome (Onivyde)]]
 
*[[Iron dextran (INFeD)]]
 
*[[Iron dextran (INFeD)]]
 
*[[Iron sucrose (Venofer)]]
 
*[[Iron sucrose (Venofer)]]
 
*[[Itraconazole (Sporanox)]]
 
*[[Itraconazole (Sporanox)]]
 
*[[Ixabepilone (Ixempra)]]
 
*[[Ixabepilone (Ixempra)]]
−
*[[Ixazomib (Ninlaro)]] '''FDA approved 11/20/2015'''
+
*[[Ixazomib (Ninlaro)]]
  
 
==J==
 
==J==
Line 330: Line 330:
 
*[[Lenalidomide (Revlimid)]]
 
*[[Lenalidomide (Revlimid)]]
 
*[[Lenograstim (Granocyte)]]
 
*[[Lenograstim (Granocyte)]]
−
*[[Lenvatinib (Lenvima)]] '''FDA approved 2/13/2015'''
+
*[[Lenvatinib (Lenvima)]]
 
*[[Lepirudin (Refludan)]] '''discontinued'''
 
*[[Lepirudin (Refludan)]] '''discontinued'''
 
*[[Lestaurtinib (CEP-701)]] '''in clinical trials'''
 
*[[Lestaurtinib (CEP-701)]] '''in clinical trials'''
Line 385: Line 385:
 
|}
 
|}
 
*[[Nabilone (Cesamet)]]
 
*[[Nabilone (Cesamet)]]
−
*[[Necitumumab (Portrazza)]] '''FDA approved 11/24/2015'''
+
*[[Necitumumab (Portrazza)]]
 
*[[Nelarabine (Arranon)]]
 
*[[Nelarabine (Arranon)]]
 
*[[NEOD001]] '''in clinical trials'''
 
*[[NEOD001]] '''in clinical trials'''
Line 421: Line 421:
 
*[[Oprozomib (ONX 0912)]] '''in clinical trials'''
 
*[[Oprozomib (ONX 0912)]] '''in clinical trials'''
 
*[[Orteronel (TAK-700)]] '''in clinical trials'''
 
*[[Orteronel (TAK-700)]] '''in clinical trials'''
−
*[[Osimertinib (Tagrisso)]] '''FDA approved 11/13/2015'''
+
*[[Osimertinib (Tagrisso)]]
 
*[[Otlertuzumab (TRU-016)]] '''in clinical trials'''
 
*[[Otlertuzumab (TRU-016)]] '''in clinical trials'''
 
*[[Oxaliplatin (Eloxatin)]]
 
*[[Oxaliplatin (Eloxatin)]]
Line 433: Line 433:
 
*[[Paclitaxel, nanoparticle albumin-bound (Abraxane)]]
 
*[[Paclitaxel, nanoparticle albumin-bound (Abraxane)]]
 
*[[Pacritinib (SB1518)]] '''in clinical trials'''
 
*[[Pacritinib (SB1518)]] '''in clinical trials'''
−
*[[Palbociclib (Ibrance)]] '''FDA approved 2/3/2015'''
+
*[[Palbociclib (Ibrance)]]
 
*[[Palonosetron (Aloxi)]]
 
*[[Palonosetron (Aloxi)]]
 
*[[Pamidronate (Aredia)]]
 
*[[Pamidronate (Aredia)]]
 
*[[Panitumumab (Vectibix)]]
 
*[[Panitumumab (Vectibix)]]
−
*[[Panobinostat (Farydak)]] '''FDA approved 2/23/2015'''
+
*[[Panobinostat (Farydak)]]
 
*[[Pantoprazole (Protonix)]]
 
*[[Pantoprazole (Protonix)]]
 
*[[Pazopanib (Votrient)]]
 
*[[Pazopanib (Votrient)]]
Line 504: Line 504:
 
*[[Rivaroxaban (Xarelto)]]
 
*[[Rivaroxaban (Xarelto)]]
 
*[[Rociletinib (CO-1686)]] '''in clinical trials'''
 
*[[Rociletinib (CO-1686)]] '''in clinical trials'''
−
*[[Rolapitant (Varubi)]] '''FDA approved 9/1/2015'''
+
*[[Rolapitant (Varubi)]]
 
*[[Romidepsin (Istodax)]]
 
*[[Romidepsin (Istodax)]]
 
*[[Romiplostim (Nplate)]]
 
*[[Romiplostim (Nplate)]]
Line 531: Line 531:
 
*[[Sirolimus (Rapamune)]]
 
*[[Sirolimus (Rapamune)]]
 
*[[SL-401]] '''in clinical trials'''
 
*[[SL-401]] '''in clinical trials'''
−
*[[Sonidegib (Odomzo)]] '''FDA approved 7/24/2015'''
+
*[[Sonidegib (Odomzo)]]
 
*[[Sorafenib (Nexavar)]]
 
*[[Sorafenib (Nexavar)]]
 
*[[Streptozocin (Zanosar)]]
 
*[[Streptozocin (Zanosar)]]
Line 543: Line 543:
 
*[[Tabalumab (LY2127399)]] '''in clinical trials'''
 
*[[Tabalumab (LY2127399)]] '''in clinical trials'''
 
*[[Tacrolimus (Prograf)]]
 
*[[Tacrolimus (Prograf)]]
−
*[[Talimogene laherparepvec (Imlygic)]] '''FDA approved on 10/27/2015'''
+
*[[Talimogene laherparepvec (Imlygic)]]
 
*[[Tamibarotene (Amnoid)]] '''in clinical trials'''
 
*[[Tamibarotene (Amnoid)]] '''in clinical trials'''
 
*[[Tamoxifen (Nolvadex)]]
 
*[[Tamoxifen (Nolvadex)]]
Line 575: Line 575:
 
*[[Trebananib (AMG 386)]] '''in clinical trials'''
 
*[[Trebananib (AMG 386)]] '''in clinical trials'''
 
*[[Tretinoin (Vesanoid)]]
 
*[[Tretinoin (Vesanoid)]]
−
*[[Trifluridine and tipiracil (Lonsurf)]] '''FDA approved 9/22/2015'''
+
*[[Trifluridine and tipiracil (Lonsurf)]]
 
*[[Trimethoprim/Sulfamethoxazole (Bactrim DS)]]
 
*[[Trimethoprim/Sulfamethoxazole (Bactrim DS)]]
 
*[[Triptorelin (Trelstar LA)]]
 
*[[Triptorelin (Trelstar LA)]]
Line 582: Line 582:
 
==U==
 
==U==
 
*[[Ublituximab (TG-1101)]] '''in clinical trials'''
 
*[[Ublituximab (TG-1101)]] '''in clinical trials'''
−
*[[Uridine triacetate (Vistogard)]] '''FDA approved 12/11/2015'''
+
*[[Uridine triacetate (Vistogard)]]
  
 
==V==
 
==V==

Revision as of 21:33, 13 March 2017

Alphabetically

A

back to top

B

back to top

C

back to top

D

back to top

E

back to top

F

back to top

G

back to top

H

back to top

I

back to top

J

K

L

back to top

M

back to top

N

back to top

O

back to top

P

back to top

Q

R

back to top

S

back to top

T

back to top

U

V

back to top

W

back to top

X

Z

By Category

Selecting a category here will take you to a new page listing all drugs in that category (note: drug categorization is still in process so not all of these links are active).

Drugs in a REMS program

Cytotoxic Chemotherapy

back to top

Kinase inhibitors

back to top

Endocrine therapy

back to top

Investigational and Discontinued

Biologics

back to top

Supportive Medications

back to top

Radioactive agents

Benign Hematology Medications

back to top

Hematopoietic Growth Factors

back to top

Miscellaneous

back to top

Medications by Condition

back to top

Medications by Route of Administration

back to top

Medications by Year of Approval

back to top

Interesting and Helpful Links

back to top

References

  1. ↑ Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, Goldberg JM, Khatcheressian JL, Leighl NB, Perkins CL, Somlo G, Wade JL, Wozniak AJ, Armitage JO. Recommendations for the Use of WBC Growth Factors: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2015 Oct 1;33(28):3199-212. Epub 2015 Jul 13.
  2. ↑ Griggs JJ, Mangu PB, Anderson H, Balaban EP, Dignam JJ, Hryniuk WM, Morrison VA, Pini TM, Runowicz CD, Rosner GL, Shayne M, Sparreboom A, Sucheston LE, Lyman GH. Appropriate chemotherapy dosing for obese adult patients with cancer: american society of clinical oncology clinical practice guideline. J Clin Oncol. 2012 May 1;30(13):1553-61. Epub 2012 Apr 2. link to original article PubMed
  3. ↑ Mancini R, Modlin J. Chemotherapy Administration Sequence: A Review of the Literature and Creation of a Sequencing Chart. J Hematol Oncol Pharm. 2011;1(1):17-25. link to original article
Retrieved from "https://hemonc.org/w/index.php?title=Drug_index&oldid=13326"